ResMed Inc (NYSE:RMD)
$ 234.42 1.84 (0.79%) Market Cap: 34.14 Bil Enterprise Value: 34.57 Bil PE Ratio: 30.81 PB Ratio: 6.57 GF Score: 99/100

Resmed Inc at Morgan Stanley Global Healthcare Conference Transcript

Sep 12, 2022 / 12:45PM GMT
Release Date Price: $238.01 (+0.84%)
Sean M. Laaman
Morgan Stanley, Research Division - Australian Healthcare Analyst

Good morning, everybody. I'm Sean Laaman, the Australian Healthcare Analyst here at Morgan Stanley. A pleasure to welcome Bobby Ghoshal and Rob Douglas from ResMed. So welcome, gentlemen. And maybe to kick things off, Rob, if we can have you make some opening remarks.

Robert A. Douglas
ResMed Inc. - President, COO and Interim President of Sleep & Respiratory Care

Sure. Thanks, Sean. Just a bit of a description for ResMed for you all. We're the world's leading digital tech-enabled medical technology company. We're leaders in all of our markets, and our -- we're best known for treating sleep apnea, which is an incredibly common condition.

Our data suggests there's nearly a billion people with sleep apnea. There's only a few tens of millions being treated. So in our core business, we've got huge opportunity.

We have data showing that treating these patients actually makes a huge difference in their life. It actually prolongs their life. We have really good

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot